Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Study of BPP-1001 in Patients with Post-Concussion Syndrome (PCS) whose Symptoms of Neuroinflammation have Remained Unresolved

Trial Profile

A Pivotal Study of BPP-1001 in Patients with Post-Concussion Syndrome (PCS) whose Symptoms of Neuroinflammation have Remained Unresolved

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPP 1001 (Primary)
  • Indications Postconcussional syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Bioscience Pharma Partners
  • Most Recent Events

    • 31 Oct 2018 New trial record
    • 24 Oct 2018 According to a Bioscience Pharma Partners (BPP) media release, this study is scheduled for H1 2019, following which BPP will actively seek breakthrough therapy status for the compound.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top